Cell Metab: Compound A-roglitazone can eliminate side effects of diabetes treatment

Introduction: It is speculated that there are more than 100 million people diagnosed with diabetes in China, which has been on the rise year by year in recent yearsThere are many types of sugar-lowering drugs used clinically, among which roglitazone tablets can play a good role in lowering blood sugarHowever, because roglitazone tablets have many adverse reactions, especially heart disease and heart failure, was once banned in countries such as Europe and the United States, may be published may be the University of Texas Southwestern Medical Center on May 14 in the journal Cell Metabolism, a new study shows that combination of drugs (the compound A-roglitone) can eliminate the side effects of diabetes treatmenta new study from the University of Texas Southwestern Medical Center suggests that an effective but largely abandoned treatment for type 2 diabetes could be used again with another drug to eliminate problematic side effects1999, Rosiglitazone, sold under the Avandia brand, was approved by the U.SFood and Drug Administration (FDA) as the main drug for type 2 diabetes, improving insulin sensitivity and glucose toleranceRoglitazone lost popularity after studies raised concerns about the risk of heart attack, osteoporosis, and evidence of weight gain and fluid retention in some patientsin a study published this month in Cell Metabolism, researchers showed how adding a second experimental drug, called compound A, activates receptors in fat cells and specific immune cells called G-protein conjugate receptor 120 (GPR120) to supplement the role of roglitonandand and allow for lower dosesIn the study of mouse models, the combination of compound A and the smallest dose of roglitazone produced an insulin hypersensitivity similar to the maximum dose of roglitazone, the report said"The very low doses we used in the experiment showed no side effects, no weight gain, no fluid retention," said Dayoung Oh, a researcher at the Diabetes Research Center at the University of Texas, The University of Texas, And a researcher at the University of Texas Southwestern Medical Center and senior author of the study.
more research is needed to test whether low doses of roglitazone cause bone loss and heart problems, but these effects are likely to be eliminated or mitigated by reducing the dose of roglitazone,Illustrated Summary2010, the FDA published prescription and dispensing limits on the drug in a study of increased risk of heart attack in patients with roglitazoneThe drugs were reduced in 2013 and were completely removed in 2015Although the fda later determined that the data did not show that roglitazone increased the risk of heart attack, it was completely removed in 2015 However, the use of roglitazone remains low "Roglitazone has long been used to treat type 2 diabetes and insulin resistance," said Although there are other drugs for type 2 diabetes, roglitazone is very good and very effective But at the same time, there are some serious side effects, including weight gain, fluid retention and so on about 34 million Americans have diabetes, 90 to 95 percent of them with type 2 diabetes, according to the U.S Centers for Disease Control and Prevention The disease can lead to kidney disease or heart disease and stroke, and can be fatal current research has found that the anti-diabetic target PPARy, which acts on fat cells, can also increase its positive anti-diabetes effects by combining with catalysts or agonists to stimulate the activity of GPR120 this study shows that compound A is a small molecule developed by Merck and acts very similar to omega-3 fatty acids rich in fish oil, a natural GPR120 catalyst, which reduces inflammatory responses and increases insulin sensitivity The study showed that while mice given the lowest dose of roglitazone alone did not show an improvement in insulin sensitivity, mice given the compound a compound A and low dose roglitazone increased insulin sensitivity said she wanted to work with interested clinical researchers to test compound A to improve the effectiveness of roglitazone and reduce the side effects of low doses of roglitazone she plans to do further research to reveal the specific mechanisms by which GPR120 activates ways to reduce the side effects of roglitazone "We hope to treat type 2 diabetes in a more effective way with lower doses of roglitazone without side effects," Oate said "